What is it about?
Erwinia chrysanthemi L-asparaginase (ErA) is an enzyme, used as treatment for childhood leukaemia. When it is manufactured, certain conditions during processing may force a small proportion of the enzyme to change shape very slightly. The resulting materials are still efficacious and active, but needed to be understood in terms of control of the manufacture. Our paper shows how to control the formation of these shape (conformational) variants of the enzyme during manufacture.
Featured Image
Why is it important?
Regulators expect that biopharmaceutical manufacturers must continuously improve their manufacturing processes. Our paper shows our efforts to do this. It is quite likely than many proteins and enzymes used as medicines undergo these slight changes, and other manufacturers will be expected to characterise and understand them.
Perspectives
This is a follow-up to our earlier paper in Pharmaceutical Research (2015) where we characterised the structure of these conformational ErA variants. In this paper we show how the manufacturing process influences the formation of the variants.
Dr David Gervais
Porton Biopharma Ltd
Read the Original
This page is a summary of: Understanding the process-induced formation of minor conformational variants of Erwinia chrysanthemi l-asparaginase, Enzyme and Microbial Technology, March 2017, Elsevier,
DOI: 10.1016/j.enzmictec.2016.12.003.
You can read the full text:
Contributors
The following have contributed to this page